
Ardelyx (ARDX) Stock Forecast & Price Target
Ardelyx (ARDX) Analyst Ratings
Bulls say
Ardelyx Inc. demonstrates a positive outlook fueled by the anticipated growth of Xphozah's contributions, supported by strategic investments in its patient assistance program and sales efforts. The revenue forecasts for IBSRELA have been revised upward, with projected figures of $422 million for FY26 and $878 million for FY29, reflecting strong market demand and effective prescription uptake. Clinical evidence showcases significant improvements in patient outcomes, particularly for those with severe constipation, which underscores the therapeutic efficacy of Ardelyx's offerings and enhances the company’s market position.
Bears say
Ardelyx Inc's financial outlook is negatively impacted by a decrease in gross-to-net (GTN) margins for its product Ibsrela, which fell to 31% in 3Q25 from 32.2% in 2Q25, reflecting potential pricing pressures. Additionally, despite promising clinical results for Xphozah in serum phosphate reduction, changes to reimbursement pricing structures could hurt the overall revenue potential for both products. Furthermore, the company's guidance for peak net sales exceeding $1 billion for Ibsrela appears unattainable, particularly if it fails to secure critical product labeling features necessary for market competitiveness.
This aggregate rating is based on analysts' research of Ardelyx and is not a guaranteed prediction by Public.com or investment advice.
Ardelyx (ARDX) Analyst Forecast & Price Prediction
Start investing in Ardelyx (ARDX)
Order type
Buy in
Order amount
Est. shares
0 shares